Gt biopharma announces updated interim gtb-3550 trike™ clinical trial results

Beverly hills, calif., march 17, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary nk cell engager (trike™) protein biologic technology platform is pleased to announce updated interim phase i/ii clinical trial results for the company's lead therapeutic candidate, gtb-3550, being evaluated for the treatment of high-risk myelodysplastic syndromes (mds) and refractory/relapsed acute myeloid leukemia (aml).
GTBP Ratings Summary
GTBP Quant Ranking